Medtronic has lined up a whole pipeline of new devices – and it will need them.
Yesterday’s clinical study success has underlined VTV's status as a small-cap bet on Alzheibetes.
Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.